Investors Invited to Participate in ImmunityBio, Inc. Securities Fraud Class Action Lawsuit

ImmunityBio, Inc. Class Action Overview

In an exciting development for investors, the Rosen Law Firm, a prominent global law firm specializing in investor rights, has announced the opportunity for buyers of ImmunityBio, Inc. (NASDAQ: IBRX) securities to join a class action lawsuit. This pertains specifically to securities purchased between January 19, 2026, and March 24, 2026, inclusive. Investors are encouraged to act quickly, as the lead plaintiff deadline is looming, set for May 26, 2026.

Who Can Join the Class Action?

The class action invites individuals who purchased ImmunityBio securities during the defined Class Period. By participating, these investors might be entitled to recover damages without needing to pay upfront costs through a contingency fee arrangement. This means they could potentially receive compensation should the lawsuit be successful, with the law firm's fees contingent upon winning the case instead of being paid out of pocket.

Next Steps for Investors

Interested parties can easily join the class action by visiting the Rosen Law Firm's submission page. Alternatively, they can contact Phillip Kim, Esq., at the firm, toll-free, at 866-767-3653, or via email at [email protected]. It's vital to note that a class action lawsuit has already been filed; however, individuals who wish to serve as lead plaintiffs must formally move the court no later than the deadline.

The Importance of Lead Plaintiffs

Becoming a lead plaintiff means taking on the responsibility of representing the interest of all class members in the lawsuit. The Rosen Law Firm emphasizes the importance of selecting a lawyer who has a proven success record in significant securities class actions. Numerous law firms announce these types of lawsuits, but many do not possess the necessary experience or resources to effectively navigate such cases. Rosen Law Firm's track record speaks for itself; it has achieved significant settlements on behalf of investors, showcasing a robust understanding of securities law.

Background on the Lawsuit

The crux of the ImmunityBio class action lawsuit revolves around allegations of misleading statements made by company executives about their product, Anktiva. The lawsuit asserts that Patrick Soon-Shiong and other defendants overstated the capabilities of Anktiva during the Class Period. Due to these exaggerations, statements regarding ImmunityBio’s business and operational health were deemed materially false or misleading. As the true state of affairs came to light, investors allegedly faced significant losses.

Conclusion and Further Recommendations

If you are among the investors who bought ImmunityBio securities during the Class Period, this is a critical moment to act. While a class has not yet been certified, potential claimants have the option to engage counsel of their choice or remain an absent class member without taking immediate action. Regardless, it is essential for investors to remain informed and consider their options carefully as this case unfolds, especially as it could affect their financial interests significantly.

For ongoing updates regarding the case and other potential class actions, follow the Rosen Law Firm on their LinkedIn or Twitter. The firm is dedicated to advocating for shareholder rights and ensuring fair treatment in the financial markets, emphasizing its commitment to its clients’ interests.